期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

去铁敏对缺血再灌注组织的保护作用 被引量：1

Protective Effect of Deferoxamine on Tissue with Ischemia-reperfusion
下载PDF
导出
摘要 去铁敏作为一种经典的高效的铁离子螯合剂能降低缺血再灌注组织中铁的含量,抑制铁驱动的氧化毒性反应,从而起到对缺血再灌组织的保护作用;另外,组织中铁离子浓度的降低,使在常氧下低氧诱导因子1的降解受到阻碍、转录得以增加,最终去铁敏可以通过增加组织细胞内低氧诱导因子1的含量来发挥对缺血再灌注组织的保护作用。 As a traditional ferri ion chelator with high efficacy,Deferoxamine can protect the tissue with ischemia-reperfusion by decreasing the ferric contents in tissue with ischemia-reperfusion and in-hibiting oxidized toxic reaction promoted by ferric. Besides that, decreased ferric concentration in tissue can block thedegradation of hypoxia-inducible factor-1 （HIF-1） in normal oxygen concentration and in-crease the transcription, so deferoxamine can exert its protective effect on tissue with ischemia-reperfusion by increasing the contents of HIF in tissues and cells.
作者 冯敏 张培建 刘新颜
机构地区 扬州大学第二临床医学院普通外科
出处 《医学综述》 2008年第1期96-97,共2页 Medical Recapitulate
基金 江苏省科技厅社会发展科技项目(BS2004536) 江苏省扬州市科技局社会发展科技项目(YZ20004048)
关键词 去铁敏 低氧诱导因子1 缺血再灌注 Deferoxamine Hypoxia-inducible factor-1 Ischemia-reperfusion
分类号 R453.9 [医药卫生—治疗学]
  • 相关文献

参考文献15

  • 1Brittenham GM. Iron chelators and iron toxicity [ J ]. Alcohol, 2003,30 (2) :151-158.
  • 2Mu D, Chang YS, Vexler ZS, et al. Hypoxia-inducible factor 1α and erythropoietin upregulation with deferoxamine salvage after neonatal stroke[ J]. Exp Neurol, 2005,195(2) :407-415.
  • 3Arkadopoulos N, Vlahakos D, Kostopanagiotou G, et al. Use of iron chelation for the control of brain edema in experimental ischemic liver failure[ J]. Alimentary Tract, 2005,201 (3) : s12-s13.
  • 4夏婷,方建培.去铁胺和deferiprone的临床研究进展[J].国外医学（儿科学分册）,2005,32(1):40-42. 被引量：5
  • 5印文彩,刘锦波.去铁胺对大鼠实验性脊髓损伤的观察治疗[J].江苏大学学报（医学版）,2005,15(3):215-217. 被引量：3
  • 6张志华,李琳.脑缺血引起血清铁改变[J].临床医药实践,2005,14(7):495-496. 被引量：3
  • 7Schroder C, Heintz A, Pexa A, et al. Preclinical evaluation of coronary vascular function after cardioplegia with HTK and different antioxidant additives [ J ]. Eur J Cardiothorac Surg, 2007,31 ( 5 ) : 821-826.
  • 8Dendorfer A, Heidbreder M, Hellwig-Bllrgel T, et al. Deferoxamine induces prolonged cardiac preconditioning via accumulation of oxygen radicals[ J]. Free Radic Biol Med, 2005,38( 1 ) : 117-124.
  • 9Guelman LR, Pagotto RM, Di Toro CG, et al. Deferoxamine antioxidant activity on cerebellar granule cells T-irradiated in vitro[ J]. Neurotoxicol Teratol, 2004,26 (3) : 477-483.
  • 10Olas B, Nowak P, Kolodziejczyk J, et al. Protective effects of resveratrol against oxidative/nitrative modifications of plasma proteins and lipids exposed to peroxynitrite[ J] .J Nutr Biochem,2006,17(2) :96-102.

二级参考文献33

  • 1Olivieri NF, BrittenhamGM. Iron-chelating therapy and the treatment of thalassemia[ J]. Blood, 1997,89(3) :747-748.
  • 2Davis BA, Porer JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk β-thalassemia[J].Blood, 2000,95(4): 1229-1236.
  • 3Chan YL,Li CK,Pang LM,et al. Desferrioxamine-induced long bone changes in thalassaemic patients-radiographic features, prevalence and relations with growth[J]. Clin Radiol,2000,55(8) :610-614.
  • 4Cabutti V, Piga A. Results of long term iron-chelating therapy [ J ]. Acta Haematol, 1996,95(1 ) :26-36.
  • 5Kattamis A, Dinopoulos A,Ladis V,et al. Variations of ferritin levels over a period of 15 years as a compliance chelation index in thalassemic patients[J] .Am J Hematol,2001,68(4) :221-224.
  • 6Taher A,Sheikh-Taha M, Koussa S, et al. Comparision between deferoxamine and deferiprone( L1 )in iron-loaded thalassemia patients[ J ]. Eur J Haematol,2001,67(1) :30-34.
  • 7Olivieri NF, Brittenham GM,Mastui D,et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major[J] .N Engl J Med, 1995,332(14): 918-922.
  • 8Olivieri NF, Brittenham GM, Mclaren CE. et al. Long term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major[J]. N Engl J Med, 1998,33(7) :417-423.
  • 9Wanless IR, Sweeney G, Dhillon AP, et al. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia [ J ]. Blood, 2002, 100 ( 5 ): 1566-1568.
  • 10Lesic B,Foulon J,Camiel E,et al. Comparision of the effects of deferiprone versus Deferoxamine on growth and virulence of yersinia enterocolitical[J].Antimicrob Agents Chemother,2002,46(6):1741-1745.

共引文献8

同被引文献9

  • 1Sharp FR, Ran R, Lu A, et al. Hypoxic preconditioning protects against ischemic brain injury [J]. NeuroRx, 2004, 1(1): 26-35.
  • 2Olas B, Nowak P, Kolodziejczyk J, et al. Protective effects of resveratrol against oxidative/nitrative modifications of plasma proteins and lipids exposed to peroxynitrite [ J ] . J Nutr Biochem ,2006,17 (2) :96 - 102.
  • 3Schroder C, Heintz A, Pexa A, et al. Preclinieal evaluation of coronary vascular function after cardioplegia with HTK and different antioxidant additives [J ]. Eur J Cardiothoracic Surg,2007,31(5) : 821 -826.
  • 4Dendorfer A, Heidbreder M, Hellwig-Burgel T, et al. Deferoxamine induces prolonged cardiac preconditioning via accumulation of oxygen radicals [ J ]. Free Radic Biol Med, 2005,38(1) :117 - 124.
  • 5Sarco DP, Becker J, Palmer C, et al. The neuroprotective effect of deferoxamine in the hypoxic-ischemic immature mouse brain[J], Neurosci Lett,2000, 282(1 -2) :113 -116.
  • 6Mazure NM, Brahimi-Horn MC, Berta MA, et al. HIF-1 : master and commander of the hypoxic world. A pharmacological approach to its regulation by siRNAs [ J ] . Biochem Pharmacol,2004,68(6) :971 -980.
  • 7Brahimi- Horn C, Pouyssegur J. When hypoxia signalling meets the ubiquitin-proteasomal pathway, new targets for cancer therapy[J]. Crit Rev Oncol Hematol,2005,53(2) :115 -123.
  • 8Kim JS, He L, Lemasters JJ. Mitochondrial permeability transition: a common pathway to necrosis and apoptosis [ J ]. Biochem Biophys Res Commun, 2003 , 304 ( 3 ) : 463 - 470.
  • 9熊力,王玉柱,叶启发,明英姿,文宇.大鼠自体原位肝移植灌注模型的技术改良[J].中国普通外科杂志,2008,17(7):716-717. 被引量：19

引证文献1

二级引证文献1

医学综述
2008年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部